Invesco India Pharma and Healthcare Fund
Invesco India Pharma and Healthcare Fund portfolio holdings, Oct 2026: 15 stocks, ₹462 cr in listed equity, from Invesco Mutual Fund's monthly disclosure; changes by share count against Sep 2026.
Fund managers: Aditya Khemani
Benchmark: BSE Healthcare TRI · Riskometer: Very High · SEBI category, as filed: Sectoral Fund ·
Source: AMFI scheme summary document
The scheme's yearly running cost as a % of its assets, taken out of the NAV a little each day. A regular plan costs more: it pays a distributor's commission.
Category median: direct 1.06 %, regular 2.50 % (20 schemes) · Regular costs ₹1,890 more a year per ₹1 lakh
Of this, the base expense ratio, the part SEBI caps: direct 0.48 %, regular 2.08 %. The rest is brokerage, transaction costs and statutory levies such as GST and STT, as AMFI's file lists them.
A year, as of 21 Nov 2026. Source: AMFI · Glossary: TER
15 stocks, Oct 2026.
As the AMC's file prints % of NAV. The top 10 stocks together: 78.1%.
This month: Oct 2026
compared with Sep 2026 · by share countMoves, Oct 2026
How many stocks the scheme bought into, added to, cut or sold out of this month, by share count, so a price move alone never counts.
- New2
- Added11
- Trimmed0
- Exited0
Asset mix, Oct 2026
How much of the fund sits in listed shares; the rest is foreign shares, debt, money market, cash and other assets.
- Listed equity97.0%
- Rest, not itemised3.0%
Rest = foreign shares, debt, money market, cash, REIT/InvIT units and other assets.
Sectors and top 10, Oct 2026
Sector mix, Oct 2026
How the scheme's equity is spread across sectors at month end.
- 100.0%
AMFI's 22 sectors; one sector per stock, from the fund houses' industry labels.
Large, mid and small cap, Oct 2026
How the scheme's equity splits across large, mid and small companies, on AMFI's list.
- Small Cap33.5%
- Large Cap31.5%
- Mid Cap19.3%
- Not in AMFI's list15.7%
AMFI's list of Jun 2026.
Top 10 holdings
Its ten largest stocks, each as a share of the fund.
- 9.08%
- 8.74%
- 8.59%
- 8.49%
- 8.31%
- 7.97%
- 7.93%
- 7.31%
- 5.96%
- 5.76%
As the AMC's file prints % of NAV.
| Stock | Change | Shares before | Shares now | Difference | Change % | Value of change | Value now |
|---|---|---|---|---|---|---|---|
| SMT | New | — | 7.52 lakh | +7.52 lakh | — | +₹34.8 cr | ₹34.8 cr |
| MANKIND | New | — | 38,784 | +38,784 | — | +₹9.7 cr | ₹9.7 cr |
| APOLLOHOSP | Added | 42,818 | 51,154 | +8,336 | +19.5% | +₹7.0 cr | ₹43.2 cr |
| DIVISLAB | Added | 36,777 | 42,503 | +5,726 | +15.6% | +₹5.6 cr | ₹41.6 cr |
| MAXHEALTH | Added | 4.49 lakh | 4.76 lakh | +26,817 | +6.0% | +₹2.3 cr | ₹40.9 cr |
| SAILIFE | Added | 2.46 lakh | 2.59 lakh | +12,972 | +5.3% | +₹2.0 cr | ₹40.4 cr |
| SUNPHARMA | Added | 2.16 lakh | 2.22 lakh | +6,845 | +3.2% | +₹1.2 cr | ₹39.5 cr |
| MANIPALHOS | Added | 4.90 lakh | 5.67 lakh | +76,489 | +15.6% | +₹5.1 cr | ₹37.9 cr |
| AGARWALEYE | Added | 5.75 lakh | 7.41 lakh | +1.66 lakh | +29.0% | +₹8.5 cr | ₹37.7 cr |
| GLENMARK | Added | 90,716 | 92,796 | +2,080 | +2.3% | +₹0.48 cr | ₹21.3 cr |
| TORNTPHARM | Added | 44,689 | 45,588 | +899 | +2.0% | +₹0.41 cr | ₹21.0 cr |
| KIMS | Added | 2.76 lakh | 2.97 lakh | +21,184 | +7.7% | +₹1.5 cr | ₹20.8 cr |
| ASTERDM | Added | 1.24 lakh | 2.51 lakh | +1.27 lakh | +101.8% | +₹8.6 cr | ₹17.1 cr |
Value of change = the difference in shares × this month's price in the AMC's file. Value now = the whole holding's market value in that file (an exit: last month's).
Equity rows as disclosed, Oct 2026. Source: Invesco Mutual Fund monthly portfolio. Report a wrong number
Large, mid and small caps, % of net assets, last 12 months
AMFI list in force each month
| Month | Large | Mid | Small | Not in AMFI's list | AMFI list |
|---|---|---|---|---|---|
| Oct 2026 | 30.6% | 18.7% | 32.5% | 15.3% | Jun 2026 |
| Sep 2026 | 29.8% | 16.4% | 32.8% | 8.0% | Jun 2026 |
Equity holdings' % of net assets each month, by AMFI's cap list in force that month.
Portfolio turnover, from holdings
equity only · month-end snapshots
| Month | Bought | Sold | Turnover |
|---|---|---|---|
| Oct 2026 | ₹87.2 cr | ₹0.00 cr | 0.0% |
| Sep 2026 | — | — | — |
The lower of bought and sold over the average equity value, from month-end holdings; it can differ from the fund house's own figure.
| Period | Return | From | To |
|---|---|---|---|
| Since first NAV | +7.58 % in total | 10 Sep 2026 · NAV ₹10.0200 | 20 Nov 2026 · NAV ₹10.7800 |
Past performance may not be sustained in future.
Change in the plan's NAV between the two dates shown, as AMFI publishes the NAVs (plan code 154547).
Not enough NAV history stored yet for rolling returns, calendar-year returns and a monthly SIP.
IDCW (dividend) history
0 declarations · as of 4 Nov 2026 · Source: AMFI
IDCW (formerly "dividend") declared per unit of each IDCW plan, as AMFI lists it.
Embed this card
Copy this into any web page. The image carries its source, date and a link back; it is redrawn each night.
- Mirae Asset Healthcare Fund45.8% overlap10 in common
- SBI Healthcare Opportunities Fund44.4% overlap12 in common
- HDFC Pharma and Healthcare Fund41.0% overlap11 in common
- LIC MF Healthcare Fund39.7% overlap10 in common
- PGIM India Healthcare Fund39.5% overlap10 in common
Overlap is the sum, over stocks both hold, of the smaller of the two weights. A measured likeness, not a suggestion to switch.
- 19 Nov 2026 · TER change: Invesco India Pharma and Healthcare Fund: AMFI TER file of 19 Nov 2026: direct plan 1.90% (was 1.91%); regular plan 3.79% (was 3.80%); previous file 18 Nov 2026
- 9 Nov 2026 · TER change: Invesco India Pharma and Healthcare Fund: AMFI TER file of 9 Nov 2026: direct plan 1.91% (was 1.92%); previous file 8 Nov 2026
- 8 Nov 2026 · TER change: Invesco India Pharma and Healthcare Fund: AMFI TER file of 8 Nov 2026: direct plan 1.92% (was 1.93%); regular plan 3.80% (was 3.81%); previous file 7 Nov 2026
- 7 Nov 2026 · TER change: Invesco India Pharma and Healthcare Fund: AMFI TER file of 7 Nov 2026: regular plan 3.81% (was —); previous file 7 Nov 2026
- 1 Nov 2026 · TER change: Invesco India Pharma and Healthcare Fund: AMFI TER file of 1 Nov 2026: direct plan 1.93% (was 0.59%); regular plan — (was 2.47%); previous file 30 Sep 2026
From AMFI's own files (scheme summary documents, NAV history, TER), as they stood on the day shown.
Questions about Invesco India Pharma and Healthcare Fund
from the figures on this pageWhat are the top holdings of Invesco India Pharma and Healthcare Fund?
At Oct 2026 end, Invesco India Pharma and Healthcare Fund held 15 stocks (97.0% of the fund in equity). Largest: Apollo Hospitals Enterprise 9.08%, Divi's Laboratories 8.74%, Max Healthcare Institute 8.59%, Sai Life Sciences 8.49%, Sun Pharmaceutical Industries 8.31%; the top 10 make up 78.1%. Funds holding Apollo Hospitals Enterprise · Funds holding Divi's Laboratories · Funds holding Max Healthcare Institute
What portfolio changes did Invesco India Pharma and Healthcare Fund make in Oct 2026?
Compared with Sep 2026, by share count: 2 new, 11 added, 0 trimmed, 0 exited. Largest by value: Sahajanand Medical Technologies (new), Mankind Pharma (new), Apollo Hospitals Enterprise (added), Divi's Laboratories (added).
Who manages Invesco India Pharma and Healthcare Fund?
AMFI's scheme summary document names Aditya Khemani for Invesco India Pharma and Healthcare Fund (Invesco Mutual Fund). Aditya Khemani, fund manager portfolio
All schemes of Invesco Mutual Fund →
Mutual fund investments are subject to market risks; read all scheme related documents carefully.